GPA and MPA are rare and potentially life-threatening diseases, which affect small and medium-sized blood vessels. The FDA approval was based on data from the PePRS phase IIa,
ST266 is a novel “secretome,” cell-free platform biologic, containing hundreds of proteins and other biological factors involved in cellular healing. For delivery to the optic nerve and brain,
The regulator has expanded the use of Dysport for injection to treat upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral
“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D.,
The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the treatment of cataplexy and excessive daytime sleepiness (EDS) in
“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive
Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is being developed
The initial focus is on developing a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha (FAP). FAP is highly expressed in many epithelial cancers,
GBS is a rare, acute and antibody-mediated autoimmune disease that will affect the peripheral nervous system. The disease currently has no approved therapies in the US. Earlier, the
“There is a pressing need for effective treatments for patients suffering from the profound defects associated with FAOD, and we believe REN001 represents a promising new therapy. Orphan
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.